X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New medicines are part of the solution to hold down future health care costs

By Amey Sutkowski  |    June 28, 2017
Innovative medicines improve patient outcomes and can yield significant economic savings. The introduction of a medicine by 2020 that delays the onset of Alzheimer’s disease by just five years...   Read More

More than 50 medicines and vaccines in development for HIV infection, treatment and prevention

By Andrew Powaleny  |    June 27, 2017
From the introduction of anti-retroviral therapy (ART) in the mid-1990’s, to the discovery of medicines that prevent the transmission of HIV, America’s biopharmaceutical companies are leading the ...   Read More

New data put medicine costs and spending in context

By Holly Campbell  |    June 26, 2017
We are in a new era of medicine where breakthrough science is transforming patient care and enabling us to more effectively treat chronic diseases, like cancer and diabetes, which are the biggest...   Read More

Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea

By Nicole Longo  |    June 26, 2017
A number of proposals have been thrown around as part of the health care debate. One idea is to repeal the noninterference clause in Medicare Part D. Doing so would allow the Secretary of Health...   Read More

Ask About Adherence: Discussion on medication adherence as national priority

By Guest Contributor  |    June 21, 2017
Ask About Adherence is a blog series featuring discussions with experts and new medication adherence resources. In this post, Sloane Salzburg, M.S, executive director of Prescriptions for a...   Read More

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

By Nicole Longo  |    June 20, 2017
In case you missed it, the Atlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no...   Read More

Medicare Monday: How government price setting in Part D could reduce innovation, shorten life expectancy for beneficiaries

By Nicole Longo  |    June 19, 2017
Today, we are diving into the conversation about how government price setting proposals could impact the Medicare Part D program and beneficiaries. Imposing Veterans Administration (VA)-style...   Read More

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

By Kevin Haninger  |    June 14, 2017
Now more than ever, innovative therapies are transforming care and providing cures for patients fighting life-threatening diseases.  In the midst of this medical progress, other health care...   Read More

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

By Mark Grayson  |    June 13, 2017
Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with...   Read More

Examining the brain in The New Era of Medicine

By Andrew Powaleny  |    June 13, 2017
Biopharmaceutical innovation is powering a rapid pace of medical breakthroughs and scientific advancements.  America’s biopharmaceutical companies are working day in and day out to uncover new...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates